Email updates

Keep up to date with the latest news and content from Journal for ImmunoTherapy of Cancer and BioMed Central.

This article is part of the supplement: Abstracts of the 28th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)

Open Access Poster presentation

Expression of cancer testis antigens and its correlation with clinicopathological parameters in hepatocellular carcinoma

Meng Wang12*, Xin-feng Chen26, Zhi-qin Li3, Zhen Zhang26, Dong-li Yue26, Yan-hong Liu1, Dong Jiang1, Yu-ling Sun4, Yong-fu Zhao4, Shu-huan Wu3, Jian-sheng Li1 and Yi Zhang256

  • * Corresponding author: Meng Wang

Author Affiliations

1 Department of Gastroenterology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

2 Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

3 Department of Infectious Diseases, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

4 Department of Hepatobiliary Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

5 Department of Bioengineering, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

6 Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

For all author emails, please log on.

Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):P250  doi:10.1186/2051-1426-1-S1-P250


The electronic version of this article is the complete one and can be found online at: http://www.immunotherapyofcancer.org/content/1/S1/P250


Published:7 November 2013

© 2013 Wang et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background

Many therapies such as surgery, chemical or physical approaches have been used for treatment of HCC; however, the outcome is still poor. Cancer immunotherapy is considered to be one of the promising strategies in recent years.

Methods

Expression of CTAs genes including MAGE A3, MAGE A4, MAGE C2 and NY-ESO-1 genes was detected with reverse transcription polymerase chain reaction (RT-PCR) in HCC tissues and corresponding adjacent non-cancerous tissues from 71 HCC patients.

Results

87.3% of HCC tumor tissue samples expressed at least 1 CTAs. HCC adjacent non-cancerous tissues did not express CTAs. 78.9% tumor tissue samples expressed MAGE-A3 mRNA, 33.8% samples expressed MAGE-A4 mRNA, 74.6% samples expressed MAGE-C2 mRNA and 14.1% samples expressed NY-ESO-1 mRNA. The expression of CTAs showed correlation with Ki67(r=0.27, P=0.02) and tumor stages (r=0.31, P=0.01), no correlation with clinical parameters such as age, gender, ALT, HLA-A2 positive, CA125, CA199, HBV or HCV infection and tumor size (P>0.05). The expression of MAGE-A3 showed correlation with the high expressions of CEA in serum (r=0.30, P=0.03), AFP in serum (r=0.26, P=0.03) and lymph node metastases (r=0.30, P=0.01).

Conclusion

Our findings demonstrate the cancer testis expression of CTAs genes show correlations with tumor stages and proliferation and may represent useful targets for tumor specific immunotherapy in HCC patients.

Table 1. Clinicopathological characteristics of the HCC patients